Bone Marrow Transplantation,
Journal Year:
2022,
Volume and Issue:
57(8), P. 1217 - 1239
Published: May 19, 2022
For
over
two
decades,
the
EBMT
has
updated
recommendations
on
indications
for
haematopoietic
cell
transplantation
(HCT)
practice
based
clinical
and
scientific
developments
in
field.
This
is
eighth
special
report
HCT
haematological
diseases,
solid
tumours
immune
disorders.
Our
aim
to
provide
general
guidance
according
prevailing
countries
centres.
In
order
inform
patient
decisions,
these
must
be
considered
conjunction
with
risk
of
disease,
procedure
non-transplant
strategies,
including
evolving
cellular
therapies.
techniques
are
constantly
we
make
no
specific
recommendations,
but
encourage
harmonisation
practice,
where
possible,
ensure
experience
across
can
meaningfully
aggregated
via
registry
outputs.
We
also
recommend
working
JACIE
accreditation
standards
maintain
quality
laboratory
components
benchmarking
survival
outcomes.
Since
last
edition,
COVID-19
pandemic
affected
decision
making
activity
indications.
Although
full
impact
yet
determined,
that
delivered
ongoing
reference
national
guidance,
accordance
current
local
conditions.
Bone Marrow Transplantation,
Journal Year:
2023,
Volume and Issue:
58(6), P. 647 - 658
Published: March 6, 2023
Abstract
In
2021,
47,412
HCT
(19,806
(42%)
allogeneic
and
27,606
(58%)
autologous)
in
43,109
patients
were
reported
by
694
European
centers.
3494
received
advanced
cellular
therapies,
2524
of
which
CAR-T
treatments,
an
additional
3245
DLI.
Changes
compared
to
the
previous
year
treatment
(+35%),
+5.4%,
autologous
+3.9%,
more
pronounced
non-malignant
disorders.
Main
indications
for
myeloid
malignancies
10,745
(58%),
lymphoid
5127
(28%)
disorders
2501
(13%).
22,129
(90%)
solid
tumors
1635
(7%).
HCT,
use
haploidentical
donors
decreased
−0.9%
while
unrelated
sibling
increased
+4.3%
+9%.
Cord
blood
−5.8%.
Pediatric
overall
+5.6%
(+6.9%
+1.6%
autologous).
Increase
was
mainly
restricted
high-income
countries.
The
drop
activity
2020
partially
recovered
second
SARS-CoV-2
pandemic.
transplant
community
confronted
with
pandemic
challenge,
continued
providing
access
treatment.
This
annual
EBMT
report
reflects
current
activities
useful
health
care
resource
planning.
Blood,
Journal Year:
2024,
Volume and Issue:
143(19), P. 1903 - 1930
Published: Feb. 2, 2024
Abstract
Experts
from
the
European
Leukemia
Net
(ELN)
working
group
for
adult
acute
lymphoblastic
leukemia
have
identified
an
unmet
need
guidance
regarding
management
of
(ALL)
diagnosis
to
aftercare.
The
has
previously
summarized
their
recommendations
diagnostic
approaches,
prognostic
factors,
and
assessment
ALL.
current
recommendation
summarizes
clinical
management.
It
covers
treatment
including
use
new
immunotherapies,
application
minimal
residual
disease
decisions,
specific
subgroups,
challenging
situations
as
well
late
effects
supportive
care.
provides
physicians
caring
patients
with
ALL
which
be
complemented
by
regional
expertise
preferably
provided
national
academic
study
groups.
Bone Marrow Transplantation,
Journal Year:
2024,
Volume and Issue:
59(6), P. 803 - 812
Published: March 4, 2024
Abstract
In
2022,
46,143
HCT
(19,011
(41.2%)
allogeneic
and
27,132
(58.8%)
autologous)
in
41,854
patients
were
reported
by
689
European
centers.
4329
received
advanced
cellular
therapies,
3205
of
which
CAR-T.
An
additional
2854
DLI.
Changes
compared
to
the
previous
year
an
increase
CAR-T
treatments
(+27%)
decrease
(−4.0%)
autologous
(−1.7%).
Main
indications
for
myeloid
malignancies
(10,433;
58.4%),
lymphoid
(4,674;
26.2%)
non-malignant
disorders
(2572;
14.4%).
lymphomas
(7897;
32.9%),
PCD
(13,694;
57.1%)
solid
tumors
(1593;
6.6%).
HCT,
use
sibling
donors
decreased
−7.7%,
haploidentical
−6.3%
unrelated
−0.9%.
Overall
cord
blood
−16.0%.
Use
allogeneic,
a
lesser
degree
likely
reflecting
availability
new
treatment
modalities,
including
small
molecules,
bispecific
antibodies,
cells.
Pediatric
activity
remains
stable
(+0.3%)
with
differences
between
HCT.
continues
reached
cumulative
total
9039
treated
wide
across
countries.
After
many
years
continuous
growth,
application
seems
have
slowed
down.
Blood Cancer Journal,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: July 5, 2024
Abstract
Autologous(auto-)
and
allogeneic(allo-)
hematopoietic
stem
cell
transplantation
(HSCT)
are
key
treatments
for
relapsed/refractory
diffuse
large
B-cell
lymphoma
(DLBCL),
although
their
roles
challenged
by
CAR-T-cells
other
immunotherapies.
We
examined
the
trends
outcomes
DLBCL
patients
undergoing
auto-/allo-HSCT
between
1990
2021
reported
to
EBMT.
Over
this
period,
41,148
underwent
auto-HSCT,
peaking
at
1911
cases
in
2016,
while
allo-HSCT
saw
a
maximum
of
294
2018.
The
recent
decline
transplants
corresponds
increased
CAR-T
(1117
2021).
Median
age
auto-HSCT
rose
from
42
(1990–1994)
58
years
(2015–2021),
with
peripheral
blood
becoming
primary
source
post-1994.
Allo-HSCT
median
36
54
(2015–2021)
years,
mobilized
as
post-1998
reduced
intensity
conditioning
post-2000.
Unrelated
mismatched
accounted
50%
19%
2015–2021.
Three-year
overall
survival
(OS)
after
improved
56%
70%
p
<
0.001,
decrease
relapse
incidence
(RI)
49%
38%,
non-relapse
mortality
(NRM)
remained
unchanged
(4%).
After
allo-HSCT,
3-year-OS
33%
(1990–1999)
46%
(
0.001);
3-year
RI
39%
1-year-NRM
decreased
0.001).
Our
data
reflect
advancements
over
32
>40,000
transplants,
providing
insights
evaluating
emerging
therapies.
Transplantation and Cellular Therapy,
Journal Year:
2022,
Volume and Issue:
28(12), P. 810 - 821
Published: Sept. 11, 2022
This
document
is
intended
as
a
guide
for
diagnosis
and
management
of
Coronavirus
Disease
2019
(COVID-19),
caused
by
the
virus
SARS-CoV-2,
in
adult
pediatric
HCT
cellular
therapy
patients.
was
prepared
using
available
data
with
expert
opinion
provided
members
(ASTCT)
Infectious
Diseases
Special
Interest
Group
(ID-SIG)
an
update
pervious
publication.
Since
our
original
publication
2020,
NIH
IDSA
have
published
extensive
guidelines
COVID-19
which
are
readily
accessible
(
Guidelines
,
).
focuses
primarily
on
issues
pertaining
specifically
to
HCT/cellular
recipients.
Information
this
manuscript
may
change
new
information
becomes
available.
Chinese Medical Journal,
Journal Year:
2022,
Volume and Issue:
135(12), P. 1394 - 1403
Published: June 20, 2022
Abstract
Hematopoietic
stem
cell
transplantation
(HSCT)
is
a
highly
effective
and
unique
medical
procedure
for
the
treatment
of
most
hematological
malignancies.
The
first
allogeneic
was
performed
by
E.
Donnall
Thomas
in
1957.
Since
then,
field
has
evolved
expanded
worldwide.
successful
allogenic
HSCT
(allo-HSCT)
China
conducted
1981.
Although
development
allo-HSCT
lagged,
since
made
considerable
contributions
to
process
worldwide,
with
more
than
10,000
HSCTs
annually.
In
particular,
haploid
(haplo-HSCT)
technology
represented
Beijing
Protocol
demonstrated
similar
efficacy
human
leukocyte
antigen-matched
gradually
become
pre-dominant
choice
China.
Currently,
number
haplo-HSCT
procedures
exceeds
5000
per
year,
been
greatly
improved
implementing
updated
individualized
strategies
controlling
complications,
relapse,
infection
management.
addition,
innovative
technologies
developed
different
centers,
such
as
Soochow,
Zhejiang,
Fujian,
Chongqing,
Anhui,
have
emerged,
providing
inspiration
refinement
global
practice.
This
review
will
focus
on
current
activity
this
highlight
important
trends
that
are
vital
China's
process,
examining
viewpoint
future
directions.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(3), P. 532 - 532
Published: Jan. 26, 2024
Up
to
50%
of
patients
with
high-risk
myeloid
malignancies
die
relapse
after
allogeneic
stem
cell
transplantation.
Current
sequential
conditioning
regimens
like
the
FLAMSA
protocol
combine
intensive
induction
therapy
TBI
or
alkylators.
Venetoclax
has
synergistic
effects
chemotherapy.
In
a
retrospective
survey
among
German
transplant
centers,
we
identified
61
that
had
received
FLAMSA-based
venetoclax
between
2018
and
2022
as
an
individualized
treatment
approach.
Sixty
(98%)
active
disease
at
74%
genetic
features.
Patients
allografts
from
matched
unrelated,
related,
mismatched
donors.
Tumor
lysis
syndrome
occurred
in
two
but
no
significant
non-hematologic
toxicity
related
was
observed.
On
day
+30,
55
(90%)
were
complete
remission.
Acute
GvHD
II°-IV°
17
(28%)
moderate/severe
chronic
7
(12%).
Event-free
survival
overall
64%
80%
1
year
well
57%
75%
2
years,
respectively.
The
off-label
combination
FLAMSA-RIC
appears
be
safe
highly
effective.
To
further
validate
these
insights
enhance
idea
smart
conditioning,
controlled
prospective
clinical
trial
initiated
July
2023.
